이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Bio-Thera Solutions 관리

관리 기준 확인 1/4

Bio-Thera Solutions' CEO는 Shengfeng Li, Mar2019 에 임명되었습니다 의 임기는 5.25 년입니다. 는 CN¥ 1.21B 가치에 해당하는 회사 주식의 12.97% 직접 소유합니다. 1.21B. 경영진과 이사회의 평균 재임 기간은 각각 2.1 년과 5.3 년입니다.

주요 정보

Shengfeng Li

최고 경영자

CN¥2.4m

총 보상

CEO 급여 비율	n/a
CEO 임기	5.4yrs
CEO 소유권	13.0%
경영진 평균 재임 기간	1.4yrs
이사회 평균 재임 기간	5.4yrs

최근 관리 업데이트

Recent updates

Bio-Thera Solutions, Ltd. (SHSE:688177) Shares May Have Slumped 30% But Getting In Cheap Is Still Unlikely

Jun 06

Some Confidence Is Lacking In Bio-Thera Solutions, Ltd. (SHSE:688177) As Shares Slide 27%

Apr 18

Subdued Growth No Barrier To Bio-Thera Solutions, Ltd. (SHSE:688177) With Shares Advancing 30%

Mar 04

CEO

Shengfeng Li (65 yo)

5.4yrs

테뉴어

CN¥2,408,100

보상

Mr. Shengfeng Li is Founder, CEO, GM & Chairman of Bio-Thera Solutions, Ltd. from May 20, 2022. He was Founder, CEO, GM & Director of Bio-Thera Solutions, Ltd.until May 20, 2022. He was Founder, CEO & Dir...

리더십 팀

이름	위치	테뉴어	보상	소유권
Shengfeng Li	Founder	5.4yrs	CN¥2.41m	12.97% CN¥ 1.2b
Jinchen Yu	President	less than a year	CN¥2.52m	데이터 없음
Cui Hua Liu	Deputy GM	no data	CN¥2.18m	데이터 없음
Xianming Huang	SVP of Discovery Research & Director	no data	CN¥2.18m	데이터 없음
Dan Yu	Executive Director & Secretary to the Board	2.3yrs	CN¥847.90k	0.069% CN¥ 6.2m
Bryan Yu	Senior Vice President of Technology Development	no data	데이터 없음	데이터 없음
Cai Bao	Senior Vice President of Quality	less than a year	데이터 없음	데이터 없음

1.4yrs

평균 재임 기간

59yo

평균 연령

경험이 풍부한 관리: 688177 의 관리팀은 경험 (평균 재직 기간 1.3 년)으로 간주되지 않으므로 새로운 팀을 추천합니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Shengfeng Li	Founder	5.4yrs	CN¥2.41m	12.97% CN¥ 1.2b
Jinchen Yu	President	5.4yrs	CN¥2.52m	데이터 없음
Cui Hua Liu	Deputy GM	2.3yrs	CN¥2.18m	데이터 없음
Xianming Huang	SVP of Discovery Research & Director	5.3yrs	CN¥2.18m	데이터 없음
Dan Yu	Executive Director & Secretary to the Board	5.4yrs	CN¥847.90k	0.069% CN¥ 6.2m
Jun Qiu	Director	5.4yrs	데이터 없음	데이터 없음
Wang Jianping	Independent Director	5.4yrs	데이터 없음	데이터 없음
Xiao Yun Wu	Chairman of the Board of Supervisors	5.4yrs	데이터 없음	데이터 없음
Dehan Huang	Independent Director	2.3yrs	CN¥120.00k	0.046% CN¥ 4.1m
Henry Wei	Independent Director	2.3yrs	CN¥120.00k	데이터 없음

5.4yrs

평균 재임 기간

59yo

평균 연령

경험이 풍부한 이사회: 688177 의 이사회는 경험(평균 재직 기간 5.3 년)으로 간주됩니다.

Bio-Thera Solutions 관리

관리 기준 확인 1/4

주요 정보

최근 관리 업데이트

Bio-Thera Solutions, Ltd., Annual General Meeting, Apr 18, 2024

Recent updates

European Medicines Agency (EMA) Approves Bio-Thera Solutions' BAT1706 (Avzivi, bevacizumab), A Biosimilar Referencing Avastin

Bio-Thera Solutions Initiates Integrated Phase I / Phase III Clinical Trial for BAT3306, A Proposed Biosimilar of Keytruda (Pembrolizumab)

Bio-Thera Solutions Announces Regulatory Filing Acceptance for BAT2206, A Proposed Biosimilar to Stelara in the US and EU

Bio-Thera Solutions, Ltd. to Report First Half, 2024 Results on Aug 23, 2024

Bio-Thera Solutions, Ltd. (SHSE:688177) Shares May Have Slumped 30% But Getting In Cheap Is Still Unlikely

Bio-Thera Solutions Receives Positive CHMP Opinion for Avzivi (Bevacizumab), A Biosimilar Referencing Avastin

Price target decreased by 22% to CN¥42.10

First quarter 2024 earnings released: CN¥0.29 loss per share (vs CN¥0.34 loss in 1Q 2023)

Some Confidence Is Lacking In Bio-Thera Solutions, Ltd. (SHSE:688177) As Shares Slide 27%

Bio-Thera Solutions, Ltd., Annual General Meeting, Apr 18, 2024

Full year 2023 earnings released: CN¥0.95 loss per share (vs CN¥1.16 loss in FY 2022)

Bio-Thera Solutions Receives IND Clearance From US FDA to Initiate a Phase II Study for BAT8006

Subdued Growth No Barrier To Bio-Thera Solutions, Ltd. (SHSE:688177) With Shares Advancing 30%

Full year 2023 earnings released: CN¥0.97 loss per share (vs CN¥1.16 loss in FY 2022)

Bio-Thera Solutions Announces Initiation of Phase IB / IIA Clinical Trial for BAT6026

FDA Approves Bio-Thera Solutions' Avzivi (Bevacizumab-Tnjn), A Biosimilar Referencing Avastin

Bio-Thera Solutions Announces Positive Results from Phase 3 Study of BAT2206, a Proposed Biosimilar Referencing Stelara

Third quarter 2023 earnings released: CN¥0.31 loss per share (vs CN¥0.21 loss in 3Q 2022)

Chugai Pharmaceutical Co., Ltd., Roche, Genentech, Biogen MA Inc. and Bio-Thera Solutions, Ltd. Withdraw Lawsuit

FDA Approves Bio-Thera Solutions, Ltd.'s Partner Biogen Receives Notification from the United States Food and Drug Administration

Second quarter 2023 earnings released: CN¥0.27 loss per share (vs CN¥0.14 loss in 2Q 2022)

Bio-Thera Solutions, Ltd. Announces Positive Phase 1 Clinical Data for Bat8006 (Folate-Receptor-A-Adc) and Presents Phase 1 Dose Escalation Study At the Bethune Obstetrics and Gynecology Forum

Chugai Files Patent Infringement Lawsuit Against Biogen MA Inc. and Bio-Thera Solutions, Ltd. in the U.S

First quarter 2023 earnings released: CN¥0.34 loss per share (vs CN¥0.27 loss in 1Q 2022)

China NMPA Approves Bio-Thera Solutions' BAT1806, A Biosimilar to Actemra(R) (Tocilizumab)

Bio-Thera Solutions Initiates Phase III Clinical Trial for BAT2306

Third quarter 2022 earnings released: CN¥0.21 loss per share (vs CN¥0.28 loss in 3Q 2021)

Bio-Thera Solutions, Ltd. Announces First Patient Dosed in Phase 1 Study for BAT2606, a Proposed Biosimilar of Nucala (mepolizumab)

Second quarter 2022 earnings released: CN¥0.14 loss per share (vs CN¥0.27 profit in 2Q 2021)

Bio-Thera Solutions, Ltd. Announces First Patient Dosed in Phase 1 Study for Bat8009, an Antibody Drug Conjugate Targeting B7-H3 (Cd276) for the Treatment of Advanced Solid Tumors

Bio-Thera Solutions, Ltd Announces First Patient Dosed in Phase 1 Study for Bat8006, an Antibody Drug Conjugate Targeting Folate Receptor A for the Treatment of Advanced Solid Tumors

Biogen Inc. and Bio-Thera Solutions, Ltd. Present Positive Phase 3 Data for Tocilizumab Biosimilar Candidate At the Annual European Congress of Rheumatology (EULAR 2022)

Bio-Thera Solutions Announces First Patient Dosed in Australia for BAT7104, a Bispecific Antibody Targeting PD-L1 and CD47 for the Treatment of Advanced Solid Tumors

First quarter 2022 earnings released: CN¥0.27 loss per share (vs CN¥0.26 loss in 1Q 2021)

Bio-Thera Solutions, Ltd. Announces First Patient Dosed in Phase 1 Study in Australia Evaluating BAT6026, Anti-OX40 Antibody with Enhanced ADCC Effect, in Combination with BAT1308, Anti-PD-1 Antibody

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

Bio-Thera Solutions, Ltd. Announces First Patient Dosed in Australia for BAT6021, ADCC-Enhanced Monoclonal Antibody Targeting TIGIT for Treatment of Solid Tumors

Bio-Thera Solutions Announces Initiation of Phase I Clinical Trials for BAT6005, a Monoclonal Antibody Targeting TIGIT

Third quarter 2021 earnings released

Second quarter 2021 earnings released: EPS CN¥1.08 (vs CN¥0.34 loss in 2Q 2020)

Bio-Thera Solutions Announces First Patient Dosed in Phase III Clinical Trial for BAT2206

Bio-Thera Solutions Initiates Phase Iii Clinical Trial for Bat2506, A Proposed Biosimilar of Simponi® (Golimumab)

Biogen and Bio-Thera Announces Positive Results From Phase 3 Study of BAT1806

First quarter 2021 earnings released: CN¥0.26 loss per share (vs CN¥0.28 loss in 1Q 2020)

New 90-day low: CN¥25.00

Full year 2020 earnings released: CN¥1.27 loss per share (vs CN¥2.96 loss in FY 2019)

New 90-day low: CN¥25.03

Bio-Thera Solutions,Ltd. Announces FDA Accepts Biologics License Application for BAT1706, a Proposed Biosimilar to Avastin®

Bio-Thera Solutions, Ltd. Announces Initiation of Phase I Clinical Trial for BAT1308, a Monoclonal Antibody Targeting PD-1

Bio-Thera Solutions,Ltd. to Report Fiscal Year 2020 Results on Mar 05, 2021

New 90-day low: CN¥29.33

Bio-Thera Solutions Announces Licensing Agreement with Biomm S.A. to Distribute and Market BAT1706 in Brazil

New 90-day low: CN¥34.21

Bio-Thera Solutions,Ltd. Submits Marketing Authorization Application (MAA) for BAT1706, a Proposed Biosimilar to Avastin®, to European Medicines Agency (EMA)

New 90-day low: CN¥38.59

Bio-Thera Solutions,Ltd. to Report Q3, 2020 Results on Oct 30, 2020

New 90-day low: CN¥43.33

New 90-day low: CN¥43.73

New 90-day low - CN¥47.10

New 90-day low - CN¥47.90

Bio-Thera Solutions, Ltd. to Report First Half, 2020 Results on Aug 28, 2020

CEO

테뉴어

보상

리더십 팀

평균 재임 기간

평균 연령

이사회 구성원

평균 재임 기간

평균 연령